Nordic Capital acquires majority stake in Evosep

"Plesner advised Novo Holdings, Danmarks Eksport- og Investeringsfond (EIFO) and the founders as Nordic Capital agreed to acquire a majority stake in Evosep. Novo Holdings and EIFO sold their shares while the founders remain invested alongside Nordic Capital. Evosep, headquartered in Odense, is a leader in LC‑MS–based proteomics sample preparation and separation. Closing expected Q4 2025."

Plesner acted as legal adviser to Novo Holdings, Danmarks Eksport- og Investeringsfond (EIFO) and the founders in connection with Nordic Capital's acquisition of a majority stake in Evosep. The transaction sees Nordic Capital acquire a majority interest in Evosep. As part of the deal, Novo Holdings and EIFO have sold all shares held by them, while the company’s founders remain invested and will continue alongside Nordic Capital. The transaction is expected to close in Q4 2025. Evosep, headquartered in Odense, is a leading innovator in sample preparation and separation solutions for LC‑MS–based proteomics. Its technology enables high-throughput, robust and reproducible LC‑MS–based proteomics workflows, supporting translational research and biopharma applications by simplifying complex proteomics processes and accelerating biological insight and discovery. Plesner represented Novo Holdings, Danmarks Eksport- og Investeringsfond (EIFO) and the founders with a core M&A team composed by: Thomas Holst Laursen, Mikkel Rostock-Jensen, Morten Stig Ottesen, Louise Lund Amris and Marcus Nimmo Allerup Bogh.

Nordic Capital acquires majority stake in Evosep

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads